文献速递肝病

他汀类药物暴露与退伍军人事务队列中慢加急性肝衰竭发生风险降低相关

Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
PubMed 文献 · J Hepatol · 2022-01-21

该回顾性队列研究纳入2008至2018年退伍军人健康管理局诊断为肝硬化的84,963例患者,按他汀暴露分为未使用、现有使用和新起始三组。中位随访51.6个月,8,558例(10.1%)因高级别慢加急性肝衰竭(ACLF)住院。时间更新他汀使用与ACLF风险显著降低相关(HR 0.62,95%CI 0.59-0.65,p<0.001)。

要点

  • 肝硬化患者中,时间更新他汀使用与高级别ACLF风险降低相关(HR 0.62)。
  • 他汀剂量递增与ACLF风险逐步降低相关,>20 mg vs 0 mg的HR为0.61。
  • 他汀暴露每增加5个月,高级别ACLF风险降低9%(HR 0.91)。

核心结论

  • 在这项大型回顾性队列研究中,肝硬化患者使用他汀与高级别ACLF发生风险显著降低相关。

研究设计与样本

  • 回顾性队列研究,纳入2008至2018年退伍军人健康管理局诊断为肝硬化的84,963例患者。
  • 患者按他汀暴露分为未使用他汀、现有他汀使用者和新起始他汀者三组。
  • 采用Cox比例风险回归模型并结合逆概率治疗加权和边际结构模型,评估时间更新他汀暴露与首次发生高级别ACLF的关联。

主要发现

  • 基线时26.9%的患者使用他汀。
  • 中位随访51.6个月(IQR 27.5-81.4),8,558例(10.1%)患者因高级别ACLF住院。
  • 时间更新他汀使用与ACLF发生风险显著降低相关(HR 0.62,95%CI 0.59-0.65,p<0.001)。
  • 以辛伐他汀等效剂量计,时间更新他汀暴露<20 mg vs 0 mg的HR为0.75(95%CI 0.66-0.86,p<0.001),>20 mg vs 0 mg的HR为0.61(95%CI 0.58-0.64,p<0.001)。
  • 他汀暴露每增加5个月,高级别ACLF风险降低9%(HR 0.91,95%CI 0.90-0.92,p<0.001)。

临床怎么用

  • 原文结论指出,本研究结果支持他汀在未来预防肝硬化患者ACLF中可能发挥的有前景的作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDS & AIMS: There is a need to identify therapies that prevent the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis. This study sought to evaluate the association between statin exposure and the risk of developing ACLF in a large national cohort of patients with cirrhosis. METHODS: We performed a retrospective cohort study of patients diagnosed with cirrhosis within the Veterans Health Administration from 2008 and 2018. Patients were stratified into 3 groups based on statin exposure (statin naïve, existing statin user, and new statin initiator). Cox proportional hazards regression models with inverse probability treatment weighting and marginal structural models were utilized to comprehensively address potential confounding in estimating the association between time-updated statin exposure and first occurrence of high-grade ACLF. RESULTS: The cohort included 84,963 patients, of whom 26.9% were on a statin at baseline. A total of 8,558 (10.1%) patients with cirrhosis were hospitalized with high-grade ACLF over a median follow-up time of 51.6 months (IQR 27.5-81.4). Time-updated statin use was associated with a significant reduction in the hazard of developing ACLF (hazard ratio [HR] 0.62, 95% CI 0.59-0.65, p <0.001). Increasing doses of statin were associated with progressively reduced hazard of developing ACLF (HR 0.75, 95% CI 0.66-0.86, p <0.001 for <20 mg vs. 0 mg of time-updated statin exposure, in simvastatin equivalents; HR 0.61, 95%, CI 0.58-0.64, p <0.001 for >20 mg vs. 0 mg statin exposure). Furthermore, every additional 5 months of statin exposure was associated with a 9% reduced hazard of high-grade ACLF (HR 0.91, 95% CI 0.90-0.92, p <0.001). CONCLUSIONS: In this large, retrospective, cohort study in patients with cirrhosis, statin use was significantly associated with reduced development of high-grade ACLF. LAY SUMMARY: Statin therapy has been shown to have numerous beneficial effects in patients with chronic liver disease. This study demonstrated a strong association between statin therapy and a reduced risk of acute-on-chronic liver failure development in patients with cirrhosis. The results of this study support the promising role that statins may play in future prevention of acute-on-chronic liver failure in patients with cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Mahmud N, Chapin S, Goldberg DS, et al. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022. PMID: 35066085. doi:10.1016/j.jhep.2021.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。